Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shangkun Zhang

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Blood|April 16, 2020
Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapyWenyue Cao, Jia Wei, Na Wang, et al.
Signal Transduction and Targeted Therapy|April 11, 2022
Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCTJia Wei, Min Xiao, Zekai Mao, et al.
Journal of Hematology & Oncology|October 10, 2021
CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicityJiangzhou Shi, Zijian Zhang, Hong Cen, et al.
Frontiers in Immunology|May 16, 2022
T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell LymphomaJiachen Wang, Kefeng Shen, Wei Mu, et al.
Scientific Reports|June 21, 2022
The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activityShangkun Zhang, Chaojiang Gu, Lifang Huang, et al.
Nature Biomedical Engineering|September 11, 2023
Suppression of cytokine release syndrome during CAR-T-cell therapy via a subcutaneously injected interleukin-6-adsorbing hydrogelXianlei Li, Ningqiang Gong, Falin Tian, et al.
Transplantation and Cellular Therapy|August 23, 2021
CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell LymphomasYang Cao, Yi Xiao, Na Wang, et al.
Frontiers in Immunology|June 7, 2022
Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt LymphomaJiaying Wu, Yang Cao, Qi Zhang, et al.
Blood|November 8, 2019
Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignanciesNa Wang, Xuelian Hu, Wenyue Cao, et al.
Clinical and Translational Medicine|March 30, 2021
A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemiaChunrui Li, Wenyue Cao, Yimei Que, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Blood|April 16, 2020
Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapyWenyue Cao, Jia Wei, Na Wang, et al.
Signal Transduction and Targeted Therapy|April 11, 2022
Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCTJia Wei, Min Xiao, Zekai Mao, et al.
Journal of Hematology & Oncology|October 10, 2021
CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicityJiangzhou Shi, Zijian Zhang, Hong Cen, et al.
Frontiers in Immunology|May 16, 2022
T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell LymphomaJiachen Wang, Kefeng Shen, Wei Mu, et al.
Scientific Reports|June 21, 2022
The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activityShangkun Zhang, Chaojiang Gu, Lifang Huang, et al.
Nature Biomedical Engineering|September 11, 2023
Suppression of cytokine release syndrome during CAR-T-cell therapy via a subcutaneously injected interleukin-6-adsorbing hydrogelXianlei Li, Ningqiang Gong, Falin Tian, et al.
Transplantation and Cellular Therapy|August 23, 2021
CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell LymphomasYang Cao, Yi Xiao, Na Wang, et al.
Frontiers in Immunology|June 7, 2022
Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt LymphomaJiaying Wu, Yang Cao, Qi Zhang, et al.
Blood|November 8, 2019
Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignanciesNa Wang, Xuelian Hu, Wenyue Cao, et al.
Clinical and Translational Medicine|March 30, 2021
A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemiaChunrui Li, Wenyue Cao, Yimei Que, et al.
Pageof 2